小分子肽抗乙型肝炎病毒的实验研究  

Experimental Study for Anti-HBV Effect of a Low Molecular Weight Peptide

作　　者：张磊 陈压西[2] 齐珍元[2] 

机构地区：[1]深圳市康哲药业有限公司,广东深圳518029 [2]重庆医科大学病毒性肝炎研究所

出　　处：《中西医结合肝病杂志》2005年第6期359-361,共3页Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases

摘　　要：目的:应用2.2.15细胞株和鸭乙型肝炎病毒(DHBV)感染模型,评价小分子肽CMS017抗乙肝病毒作用。方法:①CMS017以倍比稀释浓度加入2.2.15细胞培养中,作用8天后吸取培养上清,PCR法检测HBVDNA。②建立DHBV感染模型,CMS017以60、200、600μg/kg·d-13个剂量腹腔注射给药28天,检测用药前、后血清DHBVDNA、DHBsAg变化。结果:①CMS017体外抑制DHBV呈量效关系,IC50为2.3μg/ml。②鸭体内实验中,CMS017中、高剂量组用药7天、14天开始出现血清DHBVDNA降低(P<0.01,P<0.05),持续至停药后7天。CMS017中剂量组用药后血清DHBsAg降低的时效关系与DHBVDNA完全一致。结论:CMS017具有抗乙肝病毒作用,其体内作用的量效关系待确定。Objective： To evaluate the inhibitive effect of low molecular weight peptide CMS017 on hepatitis B virus （HBV） in vitro and in v/vo .Methods： OCMS017 diluted by multiple proportions was added in the culture of 2.2.15 cell strain. After 8-day incubation, the culture supematant was obtained for the determination of HBV DNA by PCR method. ② Model of duck HBV （DHBV） infection was estabolished. CMS017 was intraperitoneally injected at dosage of 60, 200, 600μg/kg·d^-1 for 28 days, with serum levels of DHBV DNA and DHBsAg being observed. Results： O CMS017 inhibited HBV in 2.2.15 cell with dose-effect relationship, and 50 % inhibitive concentration （IC50） was 2.3μg/ml. ② After CMS107 was administrated at dosage of 200 or 600μg/kg·d^-1, lowering of duck serum DHBV DNA level appeared on day 7 or 14 （P〈0.01 or P〈0.05） and went on till day 7 later than drug removal. On administration of 200μg·kg^-1·d^-1 CMS017, the decrease of serum DHBsAg level corresponded to that of DHBV DNA. Conclusion： CMS017 exerts an anti-HBV effect, with in vivo doseeffect relationship to be determined.

关 键 词：小分子肽 乙型肝炎病毒 2.2.15细胞 鸭乙型肝炎病毒 动物模型 

分 类 号：R96[医药卫生—药理学]